HBW Insight is part of Pharma Intelligence UK Limited

This site is operated by Pharma Intelligence UK Limited, a company registered in England and Wales with company number 13787459 whose registered office is 5 Howick Place, London SW1P 1WG. The Pharma Intelligence group is owned by Caerus Topco S.à r.l. and all copyright resides with the group.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction

State Agencies Sharpen Supplement Market Oversight During Pandemic, With Industry's Thanks

Executive Summary

"We're particularly concerned about the health care area right now because obviously that's driving everything now," says Tennessee AG Herbert Slatery III.  He and CRN CEO Steve Mister spoke with HBW Insight about regulation of the consumer health marketplace with FDA suspending inspections of facilities operated by businesses manufacturing and marketing products subject to its oversight.

You may also be interested in...



For Inspection Restart, US FDA Urged To Prioritize Foreign Supply Chains, Uninspected Sites

CRN “urges FDA to pay special attention to international supply chains, ingredient identity and purity validation,” and CHPA suggests it make progress on facilities it has not previously inspected.

Silver Supplement’s Prayer For Immunity Not Answered By Industry Self-Regulation Ad Claim Review

BBB National Programs requested support for immunity boosting and safety claims televangelist Jim Bakker made for Optivida Silver Solution Liquid Solution in a video selling the product “as a treatment or cure for novel coronavirus or COVID-19."

Consumer Health Fraud: Collidial Silver A Pandemic Repeat Offender

COVID-19 makes silver a gift that keeps on giving for US regulators with another business closed by court order; Seattle area naturopath charged with selling misbranded drug as a virus prevention; FTC reaches settlements with operators of “free trial” schemes for cosmetics and supplements; FDA announces criminal convictions of two men who defrauded the agency by misbranding steroid drugs they sold OTC.

Related Content

Topics

Latest Headlines
See All
UsernamePublicRestriction

Register

RS149853

Ask The Analyst

Ask the Analyst is free for subscribers.  Submit your question and one of our analysts will be in touch.

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel